Glibenclamide: proven facts, perspectives, discussions
https://doi.org/10.14341/probl201359357-62
Abstract
Despite the discussion about cardiovascular risk glibenclamide has proved its efficacy and safety by 40 years of clinical practice. Basing on numerous experimental publications and continued clinical investigations, perspectives of glibenclamide's use in treatment of traumatic and ischemic injuries of CNS are presented.
References
1. Дедов И.И., Шестакова М.В. Сахарный диабет. Диагностика, лечение, профилактика. М 2011; 801.
2. Seino S., Shibasaki T., Minami K. Pancreatic beta-cell signaling: toward better understanding of diabetes and its treatment. Proc Jpn Acad Ser B Phys Biol Sci 2010; 86: 6: 563-577.
3. Babenko A.P., Gonzalez G., Bryan J. Two regions of sulfonylurea receptor specify the spontaneous bursting and ATP inhibition of KATP channel isoforms. J Biol Chem 1999; 274: 17: 11587-11592.
4. Proks P., Reimann F., Green N., Gribbl F., Ashcroft F. Sulfonylurea Stimulation of Insulin Secretion. Diabetes 2002; 51: Suppl 3: S368-S376.
5. Gribble F.M., Tucker S.J., Seino S., Ashcroft F.M. Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels. Diabetes 1998; 47: 9: 1412-1418.
6. Doёrschner H., Brekardin E., Uhde I. Stoichiometry of Sulfonylurea-Induced ATP-Sensitive Potassium Channel Closure. Molecular Pharmacol 1999; 55: 1060-1066.
7. Day C. ADA-EASD diabetes guidance: individualised treatment of hyperglycaemia. Br J Diabet Vasc Dis 2012; 12: 3: 146-151.
8. Amiel S.A., Dixon T., Mann R. et al. Hypoglycaemia in Type 2 diabetes. Diabet Med 2008; 25: 245-254.
9. Kahn S.E., Haffner S.M., Heise M.A. Nissen S.E., Wolski K. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
10. Aquilante C.L. Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. Expert Rev Cardiovasc Ther 2010; 8: 3: 359-372.
11. Wei H., Dalton C., Di Maso M., Kanfer I., Lubenberg R. Physicochemical characterization of five glyburide powders: a BCS based approach to predict oral absorption. Eur J Pharmac Biopharmac 2008; 69: 1046-1056.
12. Карпов О.И. Микронизированный глибенкламид - модификация лекарственной формы и кинетики, нацеленная на результат. РМЖ 2006; 26: 3-6.
13. Blume H., Ali S.L., Siewert M. Pharmaceutical Quality of Glibenclamide Products A Multinational Postmarket Comparative Study. Drug Develop Indust Pharm 1993; 19: 20: 2713-2741.
14. Chaudhary A., Nagaich U., Gulati N., Sharma V.K., Khosa R.L. et al. Enhancement of solubilization and bioavailability of poorly soluble drugs by physical and chemical modifications: A recent review. J Advanc Pharm Educ Res 2012; 2: 1: 32-67.
15. Rendell M. The Role of Sulphonylureas in the Management of Type 2 Diabetes Mellitus. Drugs 2004; 64: 12: 1335-1339.
16. Carlson R.F., Isley W.L., Ogrinc F.G., Klobucar T.R. et al. Efficacy and safety of reformulated, micronized glyburide tablets in patients with non-insulin-dependent diabetes mellitus: a multicenter, double-blind, randomized trial. Clin Ther 1993; 15: 5: 788-796.
17. Bell D.S.H. Do sulfonylurea drugs increase the risk of cardiac events? CMAJ 2006; 174: 2: 185-186.
18. O'Rourke B. Myocardial KATP Channels in Preconditioning. Circulat Res 2000; 87: 845-855.
19. Riveline J.P., Danchin N., Ledru F., Varroud-Vial M., Charpentier G. Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications. Diabetes Metab 2003; 29: 207-222.
20. Fisman E.Z., Tenenbaum A. A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. Cardiovasc Diabet 2009; 8: 38. doi: 10.1186/1475-2840-8-38.
21. Loubania M., Fowlera A., Standenb N.B. The effect of gliclazide and glibenclamide on preconditioning of the human myocardium. Eur J Pharmacol 2005; 515: 142-149.
22. Simpson S.H., Majumdar S.R., Tsuyuki R.T., Eurich D.T., Johnson J.A. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 2006; 174: 2: 169-174.
23. McAlister F.A., Eurich D.T., Majumdar S.R., Johnson J.A. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur J Heart Fail 2008; 10: 703-708.
24. Garratt K.N., Brady P.A., Hassinger N.L., Grill D.E., Terzic A., Holmes D.R. Sulfonylurea Drugs Increase Early Mortality in Patients With Diabetes Mellitus After Direct Angioplasty for Acute Myocardial Infarction. J Am Coll Cardiol 1999; 33: 119-124.
25. Schramm T.K., Gislason G.H., Vaag A., Rasmussen J.N. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011; 32: 15: 1900-1908.
26. Meier J.J., Deifuss S., Klamann A. Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes: the LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA). Exp Clin Endocrinol Diabet 2003; 111: 344-350.
27. Selvin E., Bolen S., Yeh H.-C., Wiley C., Wilson L.M., Marinopoulos S.S., Feldman L., Vassy J., Wilson R., Bass E.B., Brancati F.L. Cardiovascular Outcomes in Trials of Oral Diabetes Medications:A Systematic Review. Arch Int Med 2008; 168: 19: 2070-2080.
28. Simard J.M., Woo S.K., Bhatta S., Gerzanich V. Drugs acting on SUR1 to treat CNS ischemia and trauma. Curr Opin Pharmacol 2008; 8: 1: 42-49.
29. Simard J.M., Woo S.K., Schwartzbauer G.T., Gerzanich V. Sulfonylurea receptor 1 in central nervous system injury: a focused review. J Cerebral Blood Flow Metabol 2012; 32: 1699-1717.
30. Chen M., Dong Y., Simard J.M. Functional Coupling between Sulfonylurea Receptor Type 1 and a Nonselective Cation Channel in Reactive Astrocytes from Adult Rat Brain. J Neurosci 2003; 23: 24: 8568-8577.
31. Patel A.D., Gerzanich V., Geng Z. Glibenclamide Reduces Hippocampal Injury and Preserves Rapid Spatial Learning in a Model of Traumatic Brain Injury. J Neuropathol Exper Neurol 2010; 69: 2: 1177-1190.
32. Simard J.M., Yurovsky V., Tsymbalyuk N. et al. Protective Effect of Delayed Treatment With Low-Dose Glibenclamide in Three Models of Ischemic Stroke. Stroke 2009; 40: 2: 604-609.
33. Kunte H., Schmidt S., Eliasziw M. Sulfonylureas Improve Outcome in Patients With Type 2 Diabetes and Acute Ischemic Stroke. Stroke 2007; 38: 2526-2530.
Review
For citations:
Chepliaeva N.I. Glibenclamide: proven facts, perspectives, discussions. Problems of Endocrinology. 2013;59(3):57-62. (In Russ.) https://doi.org/10.14341/probl201359357-62
Views:
497
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
